Navigation Links
BioMS Medical to present at UBS Global Life Sciences Conference
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York.

WHEN: Monday September 22nd at 10:00am (Eastern Time)

WHERE: Grand Hyatt New York, New York

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of comp
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. BioMS Medical announces its intention to renew a normal course issuer bid
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. BioMS Medical Announces Second Quarter 2008 Results
5. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
6. BioMS Medical to present at BMO Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at Jefferies Healthcare Conference
9. BioMS Medical to present at 2008 BIO International Convention
10. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medical announces first quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... HILL, MA (12/11/2009) Boston College researchers have observed ... the first time and successfully harvested the elusive charges ... improved solar power efficiency, the authors report in the ... , When light is captured in solar cells, it ... But in order to snare these charges, the electrons ...
(Date:12/11/2009)... OSLO, December 11 Algeta ASA ... the first clinical center in the,US, the ... randomizing patients,in the phase III clinical study ... as hormone-refractory) prostate cancer,(CRPC) that has metastasized ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a ... in cancer, staph aureus, and cardiovascular disease announces ... announced today that Rosalie Dunn, Ph.D., has joined ... has over 28 years of experience working with ... to joining Gwathmey, Dr. Dunn managed multimillion dollar ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... to promote greater awareness and understanding in the ... free webinar on August 28, 2008, ORANGEBURG, ... in,polymer science, is pleased to announce it will ... "Bioabsorbable Polymers,as Biomaterials." Presented by Dr. Bruce Anneaux ...
... BOTHELL, WA and VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - ... OGX-011, also known as,custirsen sodium, received Fast Track ... in combination with docetaxel for progressive,metastatic prostate cancer. ... in prostate, lung and breast cancer, and is ...
... Cellular Platform Utilizing Cord, Blood and Menstrual Blood Derived Stem ... ... Vascular Structures, OLDSMAR, Fla., Aug. 21 Cryo-Cell,International, ... research collaboration to co-develop a combined cellular,platform therapeutic for rapidly ...
Other Biology Technology:Zeus Webinar: Bioabsorbable Polymers as Biomaterials 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 2Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 3Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration 4
(Date:12/14/2009)... N.C. As good as laparoscopy is in preventing some ... does have drawbacks, including reduced blood flow and organ dysfunction. ... through small incisions. , By adding ... surgical area during laparoscopy, researchers at Duke University Medical Center ... noninvasive surgery. , The gas ethyl nitrite (ENO) helped ...
(Date:12/13/2009)... New Haven, Conn.A team led by Yale University ... in whole blood for the first time. Their ... online publication of Nature Nanotechnology , could ... of cancer and other diseases. , ... Professor of Engineering & Applied Science, and Tarek ...
(Date:12/11/2009)... global "green" trend, educators worldwide are relying ... students, science knowledge. Studies have revealed that ... not just science scoresenvironmental-based lessons can also ... areas. Naturally, educators are interested in developing ... into the classroom in hopes of piquing ...
Breaking Biology News(10 mins):Gas improves blood flow and organ status during minimally invasive surgery 2Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Students learn environmental stewardship, improve science scores 2Keeping the suicidal soldier alive 56041 1Keeping the suicidal soldier alive 56041 2Sustainable fertilizer 3A Urine and wood ash produce large harvest 9764 1Biopolymers Symposium 2009 Offers Two for One Deal 3A Attend Retailers Scorecard Seminar and Attend the EcoLabeling Summit Free 56040 1Biopolymers Symposium 2009 Offers Two for One Deal 3A Attend Retailers Scorecard Seminar and Attend the EcoLabeling Summit Free 56040 2
... have proved that human embryonic stem cells can develop in ... become eggs or sperm. Their work opens up the possibility ... and used for assisted reproduction, therapeutic cloning and the creation ... improved treatments for patients suffering from a range of diseases. ...
... Institutet in Stockholm shows that hundreds of genes in the ... also reveals that great differences in training response may be ... genes much more forcefully. The study is published May 2 ... is very dangerous to be inactive and that regular physical ...
... if the current mortality rates continue, according to Florida ... a group of fellow scientists from across the nation. ... Right Whales in Crisis" that appears in the July ... Nowacek and his colleagues contend that while the National ...
Other Biology News:Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 3FSU scientist warns North Atlantic right whale facing extinction 2
Sterile, Cell culture tested...
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
A substrate for all AChE-based EIA kits....
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
Biology Products: